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Disrupted sleep is prevalent in both mood and thyroid disorders. Given the emerging use of thyroid hormones in the treatment
of mood disorders, we investigated the eﬀects of supraphysiological doses of levothyroxine (L-T4) on sleep. In an open-label
design, 13 healthy subjects received up to 500µg/day for an eight-week period. A baseline night was polysomnographically
recorded (PSG) followed by PSG under the maximum tolerated dose of L-T4. All subjects developed hyperthyroxinemia. The
heart rate and respiration rate increased signiﬁcantly with treatment; a signiﬁcant increase in body temperature was observed in
men but not in women. Surprisingly, treatment with supraphysiological doses of L-T4 did not cause signiﬁcant eﬀects on sleep
architecture. However, the increase in body movements and REM density was close to reaching statistical signiﬁcance. Here, we
report on the sleep data, thyroid hormone levels, and physiological parameters during sleep. We conclude that experimentally
induced hyperthyroidism does not profoundly change the sleep structure in healthy individuals underlining the good tolerability
of treatment with supraphysiological doses of L-T4 in patients with mood disorders.
1.Introduction
Neuropsychiatric manifestations occur often within the
course of primary thyroid disorders [1]. The interrelation
between psychiatric and thyroid disorders has been exten-
sively studied in the past decades [1, 2] and is currently
in the focus of modern brain imaging techniques [3]. In
hypothyroid patients, thyroid hormone treatment reduced
depressive symptoms and somatic complaints and restored
the metabolic activity in brain areas that are integral to
the regulation of mood and cognition [3]. In patients with
primary mood disorders, treatment with thyroid hormones
normalised hypoperfusion of speciﬁc brain regions associ-
ated with depression [4]. Clinical data have evidenced good
eﬃcacy of supraphysiological dosages of thyroid hormones
in the treatment of unipolar and bipolar mood disorders.
High doses of up to 600µg per day of L-T4 were surprisingly
w e l lt o l e r a t e de v e no v e rt r e a t m e n tp e r i o d so fu pt o5 1
months [5, 6], as indicated by cardiovascular monitoring,
special questionnaires [7], and measurements of bone min-
eral density [6, 8].
Disrupted sleep is considered both a prominent symp-
tom of mood disorders and a typical sign of thyrotoxicosis
[9]. In the context of supraphysiological application of
thyroid hormones in depressed patients, presumably leading
to hyperthyroxinemia [10], investigation of sleep is conse-
quently of particular interest. We, therefore, felt it was worth
investigating the eﬀects of supraphysiological doses of L-T4
on sleep architecture by means of polysomnography.
Although it is well established that various hormones
(e.g., growth hormone releasing hormone, corticotropin
releasing hormone, and prolactin) modulate sleep-wake2 Journal of Thyroid Research
activity, little is known about the eﬀects and underlying
mechanisms of changes in thyroid status on sleep [9].
Hypothyroidism, a clinical syndrome characterized by a
deﬁcient thyroidal production of thyroid hormone, has
been observed to be accompanied by increased numbers of
awakenings and a reduced amount of slow wave sleep (SWS)
in humans and rats [11]. Patients with hypothyroidism
may sleep for long periods during the day and, in severe
cases, may lapse into stupor and even coma [12]. On
the contrary insomnia is listed among the neuropsychi-
atric manifestations of thyrotoxicosis, the clinical syndrome
of hypermetabolism that results from sustained increased
serum concentrations of thyroid hormones [13]. Three stud-
ies of patients with clinical or subclinical hyperthyroidism
reported sleep problems as a frequent complaint and sleep
quality being subjectively rated as bad [14–16]. With respect
to sleep architecture, the results of some studies are in
agreement, while others contradict each other: Passouant
and coworkers [17] observed an increased sleep latency, a
reduced total sleep time, an increased REM density and
REM duration as well as a reduction in slow wave sleep
in eight patients with clinical hyperthyroidism. Kronfol
et al. [18] observed a reduced sleep eﬃciency, low delta
sleep, short REM latency, and a high REM density in one
case of thyrotoxicosis. In contrast to this ﬁnding, Dunleavy
et al. [19] reported a higher percentage of SWS during the
hyperthyroid state as compared to the sleep structure, once
the thyroid hormone levels had returned to normal in a
study of four subjects. Kales and coworkers [20] studied
six patients with clinically determined hypothyroidism and
found normal REM parameters, sleep latencies, and sleep
duration, but an increase in sleep stage 2 (S2), and a reduc-
tion of SWS. The latter was reported to return to normal
during hormone replacement therapy. The only ﬁnding that
could be replicated was reduced SWS in nine patients with
hypothyroidism Ruiz-Primo et al. [21]—rated according to
the rules of Rechtschaﬀen and Kales [22]. However, it should
be emphasized that all but one of these studies date back to a
time when a commonly accepted and reliable system of sleep
scoring was not yet available and thyroid dysfunction was
diagnosed clinically. Only in the study by Kronfol et al. [18]
were serum thyroid hormone levels determined.
Sleep disorders are of high medical and socioeconomic
relevance [23–25]. Their adequate appraisal and treatment is
essential. As polysomnography is time consuming and costly,
eﬀective preclinical diagnostic procedures are needed. Thus,
knowledgeastowhichdisorderscancausesleepdisturbances
and which diseases can present initially as a sleep disorder,
are helpful in managing the patients and in reducing the
costs of diagnostic procedures and treatment by improving
the diagnostic rationale. The present study was part of a
project that investigated diﬀerences in response to supra-
physiological doses of levothyroxine between healthy indi-
viduals and patients with refractory depression [26]. In this
study, we investigated the eﬀects of high, supraphysiological
doses of levothyroxine on sleep and other physiological
parameters (electrocardiogram, heart rate, body tempera-
ture,andrespirationrate)inhealthyindividuals.Byinducing
anexperimentalhyperthyroidstateinhealthyindividuals,we
also expected to get a clear picture of the eﬀects of hyper-
thyroidism on sleep.
2. Methods
This study was part of a series of trials to investigate
the eﬀects, tolerability, and safety of treatment with sup-
raphysiological doses of L-T4 in patients with refractory
m o o dd i s o r d e r sa n di nh e a l t h yc o n t r o l s[ 7, 10, 26]. Written
informed consent was obtained from all subjects. The study
was approved by the local ethics committee. Subjects were
reimbursed for participation.
2.1. Subjects. Thirteen healthy volunteers (6 female, 7 male;
age range: 23–50 years, mean ± SD: 36.2 ± 8.8 years)
participated. Inclusion or exclusion from the study was
determined by a semistructured medical and psychiatric
interview including a physical examination, an electrocar-
diogram (ECG), measurements of blood pressure, heart
rate and body weight, a laboratory workup including red
and white blood cell count, blood chemistry, basal TSH,
serum thyroid hormones (total thyroxine [T4], free T4 [fT4],
total triiodothyronine [T3], and free T3 [fT3]), and thyroid
autoantibodies (thyroid peroxidase antibody, thyroglobulin
antibody). The inclusion criteria were 18 to 50 years of age,
euthyroid status, absence of any signs of medical illness,
euthymic mood (as indicated by a score < 8 on the Hamilton
rating scale for depression). The exclusion criteria were: past
orcurrentthyroid,medicalorpsychiatricdisorder;substance
abuse or dependency, pregnancy or lactation; and use of any
medication or hormones, apart from oral contraception (for
details, see Bauer et al. 2002 [10]).
2.2. Procedures. After an adaptation night and baseline PSG,
the initial dose of 50µg/d of L-T4 was administered as a
single morning dose 15–30 minutes prior to breakfast. The
dosage was increased by 50µg/d every three to seven days to
achieve a dose of 500µg/d by day 42, maintaining that dose
for another two weeks. The dosage of L-T4 was not further
increased if the subject experienced intolerable symptoms
or wished to discontinue the study. In the latter case, if
the subject agreed, the highest possible L-T4 dosage was
continued for a maximum of 14 days, and discontinued
after carrying out the ﬁnal examinations. If this was not
possible, the ﬁnal examinations were done immediately,
hormoneintakewasdiscontinuedimmediately,andthesleep
recording was performed the same night. This was the case
for three subjects. For the remaining ten subjects, at the end
of the 14 days period on the maximum dosage of L-T4, all
examinations were repeated. One whole night’s sleep was
recorded in the sleep laboratory, following the same protocol
as mentioned below.
Subjects documented their medication intake, heart rate,
and possible side eﬀects every morning. At weekly visits,
the Thyroid Symptom List, a 24-item clinician-administered
instrumenttoratesignsandsymptomsofthyrotoxicosis,was
completed for each subject [10]. Safety evaluations regarding
the laboratory and cardiovascular workup were performedJournal of Thyroid Research 3
Table 1: Serum concentrations of thyroid hormones at baseline and during maximal dosage of levothyroxine (L-T4)1.
Thyroid hormone (normal range) Baseline During T4 treatment Δ2
P
Median Quartile range Median Quartile range Median Quartile range
T3 (0.8–1.6µg/L) 1.3 1.2–1.4 2.3 2.0–2.9 1.2 0.8–1.4 .0005
T4 (45–125µg/L) 89 76–91 197 169–224 108 88–136 .0002
FT3 (2.3–5.1ng/L) 4.2 3.7–4.7 6.9 5.2–7.2 2.3 1.2–3.1 .0015
FT4 (7–19ng/L) 10.8 9.2–12.2 45.8 32.6–53.6 37.5 21.7–41.5 .0002
1For abbreviations see text.
2Δ refers to intraindividual diﬀerences.
weekly until the end of treatment. For safety reasons, thyroid
function tests were monitored weekly. Compliance with
medication was monitored by weekly measurement of TSH
(thyroid stimulating hormone; usually suppressed at a L-T4
dose of >200µg/d).
2.3. Polysomographic Procedures. Before initiation of T4
administration,twosubsequentnightsofsleepwererecorded
polysomnographically, including the registration of the
following leads: vertical and horizontal electrooculogram
(EOG), electroencephalogram (EEG) with 5 leads (C3-A2,
C4-A1, C3-C4, Oz-A1, and Oz-A2), mental electromyogram
(mEMG), and EMG of both anterior tibial muscles (tEMG)
(PL-EEG, WALTER GRAPHTEC GmbH, Bad Oldesloe,
Germany). Furthermore, nasal air ﬂow, thorax movements,
snoring, electrocardiogram (ECG), and rectal body temper-
ature (W+W-Recorder Series 310; YSI Thermistorsonden,
Serie 400) were recorded.
Sleep recordings were analysed visually according to the
rules of Rechtschaﬀen and Kales [22]. To determine the
heart rate and respiration rate during sleep, the night was
divided in three thirds. For each of the sleep stages S2,
SWS, and REM, ten artefact-free 30-second-epochs were
identiﬁed in each third of the night. Within these selected
epoques, R-spikes and breaths were manually counted.
Body temperature was documented continuously by a rectal
device. The body temperature was read every 15 minutes.
The ﬁrst pre-medication night was an adaptation night and,
therefore, not used for analysis.
2.4. Statistical Analysis. To assess the eﬀect of L-T4 on hor-
mones of the hypothalamic-pituitary-thyroid (HPT) axis
( T 3 ,f T 3 ,T 4 ,f T 4 ,a n dT S H ) ,p h y s i o l o g i c a lp a r a m e t e r s( c o r e
body temperature, heart and respiration rate) and a number
of sleep parameters were taken into account. These were
time in bed (TIB), sleep period time (SPT), total sleep
time (TST), sleep eﬃciency (SEI: TST/TIB × 100), number
of changes of sleep stages (CSS), body movement index
(BMI; number of larger body movements during TST), eye
movement index (EM; number of rapid eye movements
during REM = REM densitiy), latencies to sleep stage 1 (L
S1; time from lights oﬀ until the ﬁrst occurrence of sleep
stage 1), to sleep stage 2 (L S2; time from lights oﬀ until the
ﬁrst occurrence of sleep stage 2), to slow wave sleep (L SWS;
time from lights oﬀ until the ﬁrst occurrence of slow wave
sleep), to rapid eye movement sleep (L REM; time from
falling alseep until the ﬁrst occurrence of sleep stage REM),
the amount of wakefulness (W), the duration of the sleep
stages S1, S2 SWS, and REM, and movement time (MT).
The individual diﬀerences between baseline levels and those
under treatment were assessed by Wilcoxon’s matched pairs
signed ranks test. Although there was no reason to reject
the hypothesis that the Δ-values were normally distributed
as tested by Shapiro-Wilk test, the nonparametric Wilcoxon’s
matched pairs signed ranks test was chosen instead of the t-
test for paired observations, since the sample size is small. All
tests were performed with a double sided P<. 05.
3. Results
During administration of L-T4 (mean ± SD: 476 ± 41µg/d),
serum total thyroid hormone levels (T3 and T4)a n df r e e
hormone levels (fT3 and fT4) increased signiﬁcantly (all P<
.01). Before administration of L-T4, basal TSH levels were
within the normal range of 0.4–3.5mU/L in all individuals.
As expected from an intact negative feedback control of the
HPT axis, the basal TSH values decreased signiﬁcantly (P<
.05) during L-T4 administration (Table 1). TSH was fully
suppressed in all individuals including subjects that had to
discontinue L-T4 intake early, as well as those that reached
the highest dosage. Therefore, the data of all 13 subjects
includedinthestudywasablebeusedforanalysisofthesleep
data.
The results presented in Table 2 demonstrate a statisti-
cally signiﬁcant increase in heart rate and respiration rate
duringL-T4intake.Thedataalsoshowthatthisincreaseper-
sistsduringthesleepstagesS2,SWS,andREM.Furthermore,
the data indicate that the known tendency of a slightly higher
heart rate and respiration rate in REM sleep is preserved
during L-T4 intake.
Data on nocturnal core body temperature were available
for 11 subjects only, because two subjects did not tolerate the
rectal measuring device. The mean values of body tempera-
turetendedtobeslightlyhigherduringL-T4intake;however,
the diﬀerences were not statistically signiﬁcant (Table 3). The
standard deviation calculated on the basis of measurements
read every 15 minutes, which was used as an indicator of
variability, did also not show a clear trend.
An intraindividual test (Wilcoxon’s matched pairs sing
ranks test) on homogeneity of the body temperature dis-
tributions revealed that, except for one female subject, the
diﬀerences were statistically signiﬁcant (P<. 05). For seven
of the ten subjects with statistically signiﬁcant diﬀerences,4 Journal of Thyroid Research
Table 2: Heart rate and respiration rate at baseline and during maximal dosage of levothyroxine (L-T4)1.
Physiological parameter Baseline During T4 treatment Δ2
P
Median Quartile range Median Quartile range Median Quartile range
Heart rate/beats per minute
S2 64.4 55.1–72.7 81.4 75.1–87.2 18.9 12.5–20.8 .0002
SWS 66.8 56.6–75.6 83.3 75.8–87.1 18.6 11.5–20.6 .0012
REM 72.0 56.4–74.3 84.0 76.1–88.0 14.9 10.5–20.4 .0002
Respiration rate/per minute
S2 15.3 14.2–17.0 17.4 16.4–19.7 2.0 1.6–2.9 .0010
SWS 15.3 14.5–17.4 17.2 16.2–20.3 1.6 1.1–3.0 .0005
REM 16.7 15.1–17.5 19.9 16.9–22.1 3.2 1.3–4.1 .0005
1For abbreviations see text.
2Δ refers to intraindividual diﬀerences.
Table 3: Mean core body temperature at baseline and during maximal dosage of levothyroxine (L-T4).
Temperature Baseline During T4 treatment Δ1
P
Median Quartile range Median Quartile range Median Quartile range
Both sexes n = 11
Mean 36.48 36.38–36.85 36.65 36.56–36.91 0.11 −0.18–0.33 .4014
SD 0.14 0.11–0.17 0.12 0.10–0.21 −0.02 −0.03–0.06 .9658
Females n = 6
Mean 36.77 36.44–36.87 36.64 36.56–36.91 −0.07 −0.40–0.18 .8750
SD 0.14 0.09–0.14 0.15 0.10–0.21 0.02 −0.03–0.07 .4375
Males n = 5
Mean 36.45 35.38–36.48 36.69 36.57–36.78 0.24 0.11–0.33 .0625
SD 0.17 0.17–0.17 0.12 0.11–1.14 −0.02 −0.05–−0.02 .4375
1Δ refers to intraindividual diﬀerences.
body temperature measured prior to medication was lower
than during L-T4 treatment. The three subjects with a higher
body temperature prior to L-T4 treatment were women. A
representative example of the time course of core body
temperature diﬀerences in males recorded before and during
L-T4 intake is shown in Figure 1.I nf e m a l e s ,o p p o s i t e
trends were observed in diﬀerent subjects; some showed a
decrease in core body temperature during treatment, others
an increase (see Figures 2(a) and 2(b)).
In seven out of the eleven subjects in whom core
body temperature could be sampled, the nadir of body
temperature was advanced during L-T4 intake by 15 minutes
to 270 minutes. It was most pronounced in three of these
subjects with an advance of 75, 150, and 270 minutes,
respectively. In one subject, a delay of 120 minutes occurred.
No shift was found in two subjects, while due to a dislocation
of the measuring device during sleep, the nadir could not be
determined in one further subject.
The descriptive data for the quantitative sleep data are
shown in Table 4. The medians of the individual diﬀerences
between the pre-T4 treatment night and the night during
L-T4 intake were close to zero for the entire group in the
global sleep parameters TIB and SPT although there were
marked diﬀerences in individual subjects, partly showing an
increase partly a decrease. TST tended to be shorter during

































Figure 1: Time course of core body temperature in a male subject
prior to (grey square) and during (grey circle) levothyroxine intake.
38 minutes. The SEI tended to be slightly reduced during
L-T4 intake. Since two individuals showed a pronounced
increase in their SEI with medication while nine subjects
showed the expected decrease, the diﬀerences on average
were statistically not signiﬁcant. CSS did not change notably
with L-T4.
Neither the sleep stage latencies nor their duration ex-
pressed as percentages revealed any systematic changes. Only
































































Prior to levothyroxine intake
During levothyroxine intake
(b)
Figure 2: (a) Female subject with a higher core body temperature prior to levothyroxine intake (grey square) than during levothyroxine
intake (grey circle). (b) Female subject with a lower core body temperature prior to levothyroxine intake (grey square) than during
levothyroxine intake (grey circle).
Table 4: Sleep parameters at baseline and during maximal dosage of levothyroxine (L-T4)1.
Sleep parameters Baseline During T4 treatment Δ2
P
Median Quartile range Median Quartile range Median Quartile range
TIB (min) 415 404–477 411 405–471 1 −79–43 .6772
SPT (min) 405 378– 472 401 382–440 −4 −72–39 .6848
TST (min) 384 357–399 378 341–386 −38 −61–29 .2439
SEI 89.5 86.0–95.9 90.4 86.0–92.8 −3.2 −9.3–7.2 .6484
CSS 150 141–185 157 144–180 −2 −14–17 .9324
BM 10.3 9.3–16.1 14.0 12.3–17.0 2.0 −0.4–4.5 .1272
EM 36.5 27.3–39.6 36.9 30.7–48.1 7.8 0.7–9.1 .0681
L S1 6.5 3.5–13.0 9.0 7.5–16.0 1.0 −4.0–7.0 .5295
L S2 10.5 5.0–22.5 11.0 9.0–21.5 0.0 −6.0–9.0 .6084
L S3 16.0 11.5–29.5 18.0 16.5–22.5 5.0 −5.5–10.5 .7354
L S4 23.5 14.0–39.5 23.5 19.0–28.5 4.5 −18.5–9.9 .9233
L REM 72.0 63.0–100.0 71.5 67.5–91.0 5.0 −9.0–20.5 .5417
W (%) 7.1 2.5–11.9 4.5 3.3–8.9 1.3 −8.4–6.4 .8394
S1 (%) 7.6 4.9–9.1 6.8 5.5–9.9 0.6 −2.8–1.2 1.0000
S2 (%) 48.4 40.0–51.6 48.5 37.9–51.8 −1.3 −5.8–1.9 .4548
SWS (%) 15.7 11.1–18.9 13.2 10.8–14.8 0.0 −6.2–4.3 .8394
REM (%) 20.1 16.4–22.7 21.5 17.2–23.9 0.0 −2.4–4.6 .7334
MT (%) 1.3 0.9–1.6 1.5 0.9–2.3 0.2 −0.2–1.1 .2104
1For abbreviations see text.
2Δ refers to intraindividual diﬀerences.
BM and REM densitiy. Both tended to be higher with L-T4.
The latter almost reached statistical signiﬁcance.
4. Discussion
To our knowledge, this is the ﬁrst study to investigate the
eﬀects of supraphysiological doses of L-T4 on sleep by means
ofpolysomnography.Allsubjectsdevelopedhyperthyroxine-
mia as indicated by signiﬁcantly elevated serum free thyrox-
inelevels,heartrate,andrespirationrate,andbysuppression
of basal TSH during treatment with L-T4. These results were
expected from treatment with supraphysiological doses of
L-T4 and are in line with those given in the pertinent
literature [10]. It is also well established that increased serum
levels of thyroid hormones may lead to an accelerated heart
and respiration rate [27–29].
The main ﬁnding of this study is that 8 weeks of treat-
ment with supraphysiological doses of L-T4 do not pro-
foundly inﬂuence the sleep structure. This result was unex-
pected for two reasons: (1) patients with clinical hyperthy-
roidism frequently complain about sleep disturbances [30]
and (2) previous studies have suggested a substantial role
of the HPT system in sleep endocrine activity [31], and as
evidencedinexperimentallyinducedhypothyroidconditions6 Journal of Thyroid Research
in rats [32, 33]. However, there are studies demonstrating
no alterations in sleep characteristics in subjects with overt
hyperthyroidism [34] and thyroxine-injected (euthyreot)
rats [32, 35]. Furthermore, thyrotropin-releasing hormone
(TRH) exerts only weak eﬀects on the sleep patterns of
healthy male volunteers [36]. Thus, it appears that normal
thyroid hormones are necessary for sleep but that a further
i n c r e a s ei nt h y r o i dh o r m o n el e v e l sd o e sn o tp r o d u c es i g -
niﬁcant changes in the sleep architecture underlining the
good tolerability of supraphysiological doses of L-T4 in
the treatment of mood disorders. However, we would like
to emphasize that this may be diﬀerent in patients with
clinical hyperthyroidism who may well suﬀer from sleep
disruption which is caused by higher and longer-lasting
thyroid hormone levels than those which are produced in an
eight-week experimental study.
In the male subjects, a slight increase in core body
temperature was observed consistently in all individuals.
However,markedinterindividualdiﬀerenceswerepresent.In
women, body temperature changes had opposite directions
in diﬀerent individuals. This might be due at least in part
to the inﬂuences of the menstrual cycle, which was not
controlled for. Thyroid hormones increase thermogenesis as
a result of the stimulation of numerous metabolic pathways
involved in the development and delivery of energy to the
tissues [37]. As a result, high fever (>40◦C) is a cardinal
manifestation of severe forms of thyrotoxicosis [38]. The
advancement of the nadir of body temperature that was
observed in most of the subjects might be due to the
suppression of TSH. In undisturbed sleep, a decrease in TSH
precedesthesleepphase[39].Thus,itmaybespeculatedthat
low/suppressed TSH levels could be responsible for inducing
a phase advance state.
With respect to treatment eﬃcacy in depressed patients
with L-T4, it is of great interest that in the present study
the eﬀect of L-T4 was most pronounced on REM sleep.
Although REM latency, which is delayed by a number of
antidepressive drugs (e.g., tri- and tetracyclic drugs, MAO
inhibitors) [40], did not change markedly, REM density
increased. This could be another indicator for the suggested
stimulation of the cholinergic system, which is involved in
moodregulation,byL-T4[41].Becauseofthemarkedeﬀects
of the hyperthyroxinemic state that was induced in this
study,neitherthesubjectsnorthephysicianscouldeﬀectively
be blinded. Further work to establish the eﬀect of thyroid
dysfunction on sleep has to be done.
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